Oxford Nanopore Technologies has collaborated with Singapore's National Precision Medicine Programme led by Precision Health Research, Singapore (PRECISE), to study human genetic diversity and diseases.
Oxford Nanopore’s contribution to the project involves sequencing 10,000 genomes from Singapore’s diverse population, including Malay, Indian, and Chinese communities within the PRECISE-SG100K population cohort. Utilizing its high-output PromethION 48 sequencing devices, Oxford Nanopore aims to provide detailed, comprehensive genomic data to enhance research and support precision healthcare. The project commenced in mid-2024 and is expected to span up to 12 months.
Analyst QuickTime: In July 2024 , Oxford Nanopore Technologies partnered with Plasmidsaurus, a whole-plasmid sequencing provider, to expand the plasmid sequencing industry further. The partnership aimed to leverage Oxford Nanopore’s technology to overcome the limitations of traditional plasmid sequencing methods, such as Sanger, which were limited by short read lengths and primer dependency and are confounded by GC-rich or repetitive DNA.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.